PatentMay 27, 2026, 08:33 AM
bioAffinity Technologies Receives Mexico Patent for Lung Cancer Detection
AI Summary
bioAffinity Technologies, Inc. announced it has received notification of allowance from the Mexican Institute of Industrial Property for a patent application. This patent relates to methods of predicting the likelihood of lung cancer using flow cytometry, specifically protecting the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum. The allowance expands the company's global intellectual property portfolio for its CyPath Lung diagnostic platform, strengthening its proprietary approach to detecting early-stage lung cancer in international markets and supporting shareholder value.
Key Highlights
- bioAffinity Technologies received notification of allowance for a patent application from the Mexican Institute of Industrial Property.
- The patent covers methods of predicting the likelihood of lung cancer using flow cytometry.
- It specifically protects the use of defined antibodies and porphyrin TCPP to label cell populations in sputum.
- The patent expands the company's global intellectual property portfolio for its CyPath Lung diagnostic platform.
- CyPath Lung utilizes flow cytometry and artificial intelligence for early-stage lung cancer detection.
- The company's IP portfolio now includes patents in the US, EU, China, Japan, Australia, Canada, and Mexico.
- CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value in clinical trials.
Price Impact
More from BIAF